Rivaroxaban - Austhera Biosciences
Alternative Names: AST-8294; DST-8294; KRIVALatest Information Update: 28 Oct 2023
Price :
$50 *
At a glance
- Originator DisperSol Technologies
- Developer AustinPx
- Class Amides; Anticoagulants; Antithrombotics; Cardiovascular therapies; Chlorinated hydrocarbons; Ketones; Morpholines; Oxazolidinones; Small molecules; Thiophenes
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Antiphospholipid syndrome
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Antiphospholipid-syndrome in USA (PO)
- 10 Mar 2021 Rivaroxaban licensed to Austhera Biosciences prior to March 2021 (Austhera Biosciences pipeline, March 2021)
- 25 Sep 2020 DisperSol Technologies has patent protection for KinetiSol® technology before September 2020 (DisperSol Technologies website, September 2020)